# Semaglutide Dosage: FDA-Labeled Doses and Clinical Trial Protocols

> Semaglutide dosing protocols from STEP and PIONEER clinical trials: titration schedules, half-life data, oral vs. subcutaneous administration, and discontinuation findings.

## Semaglutide Dosing Protocols in Clinical Studies

Semaglutide is an FDA-approved prescription compound. The following describes the dose titration schedules studied in clinical trials and reflected in FDA-approved labeling — not a personal dosing recommendation.

**STEP trial protocol (subcutaneous, weight management):**
- Weeks 1–4: 0.25 mg subcutaneous once weekly
- Weeks 5–8: 0.5 mg subcutaneous once weekly
- Weeks 9–12: 1.0 mg subcutaneous once weekly
- Weeks 13–16: 1.7 mg subcutaneous once weekly
- Week 17+: 2.4 mg subcutaneous once weekly (maintenance)

This titration produced the 14.9% mean weight reduction at 68 weeks in STEP 1 [1].

**SUSTAIN programme (subcutaneous, type 2 diabetes):** Doses of 0.5 mg and 1.0 mg subcutaneous once weekly in SUSTAIN 1–6. HbA1c reductions of approximately 1.5 percentage points.

**PIONEER programme (oral, type 2 diabetes):** 3 mg once daily (weeks 1–4), 7 mg once daily (weeks 5–8), 14 mg once daily maintenance (week 9+). HbA1c reductions of 1.0–1.4 percentage points at 26 weeks [9]. Administration requirement: fasting with up to 120 mL water, 30-minute waiting period [10].

## Semaglutide Half-Life and Pharmacokinetics

Semaglutide elimination half-life: approximately 145–168 hours for both subcutaneous and oral formulations, enabling once-weekly subcutaneous dosing [10]. This compares to a half-life of approximately 2 minutes for native GLP-1 [12].

Steady-state plasma concentrations are reached after 4–5 weeks of continuous once-weekly administration [10]. Oral bioavailability is approximately 0.8%.

Drug interactions: dedicated pharmacokinetic study showed no clinically relevant effects on AUC for metformin, warfarin, or digoxin. Atorvastatin Cmax reduced approximately 38% — total AUC unchanged; no dose adjustment required [11].

**How long does Semaglutide stay in your system?** Elimination half-life approximately 1 week (145–168 hours); steady-state reached after 4–5 weeks of continuous weekly administration [10].

## Discontinuation findings in Semaglutide trials

Weight regain following discontinuation is well-documented. STEP 1 trial extension: approximately 11.6 percentage points weight regain within one year of discontinuing semaglutide [3].

STEP 4 (withdrawal design): participants who continued semaglutide lost an additional 7.9% at 48 weeks; those switched to placebo regained 6.9% of body weight. Net treatment difference at 68 weeks: 14.8 percentage points favoring continued semaglutide [4].

GI symptoms generally resolve within weeks of discontinuation. No physiological withdrawal syndrome has been identified in trial data.

**What are the proper doses for Semaglutide?** STEP protocols used a five-step titration: 0.25 mg/week to 2.4 mg/week maintenance over 16 weeks. PIONEER oral protocol: 3 mg/day to 14 mg/day maintenance over 8 weeks [1, 9]. These are FDA-labeled doses from clinical trials, not individual dosing recommendations.

## References

[1] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
[3] Wilding JPH, et al. Weight regain after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. DOI: 10.1111/dom.14725
[4] Rubino D, et al. The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. DOI: 10.1001/jama.2021.3224
[8] Kosiborod MN, et al. Semaglutide improves cardiometabolic risk factors: STEP 1 and 4. Diabetes Obes Metab. 2023;25(2):468-478. DOI: 10.1111/dom.14890
[9] Thethi TK, et al. PIONEER programme. Diabetes Obes Metab. 2020;22(8):1263-1277. DOI: 10.1111/dom.14054
[10] Yang X-D, Yang Y-Y. Clinical Pharmacokinetics of Semaglutide. Drug Des Devel Ther. 2024;18:2555-2569. DOI: 10.2147/DDDT.S470826
[11] Tamayo-Trujillo R, et al. Molecular mechanisms of semaglutide and liraglutide. Front Nutr. 2024;11:1398059. DOI: 10.3389/fnut.2024.1398059
[12] Papakonstantinou I, et al. Spotlight on the Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024;46(12):13632-13656. DOI: 10.3390/cimb46120872

---

A trial-by-trial weighing of the semaglutide evidence record — STEP, SUSTAIN, SELECT, PIONEER — reported plainly, cited fully, and sold by no one.